Home > Press > NanoSight announces interactive webinar on September 9th on the Characterization of Protein Aggregation
NanoSight’s founder and CTO, Dr Bob Carr |
Abstract:
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology will host an interactive webinar on the subject of the characterization of protein aggregation. It will be held on Thursday 9th September, 0700 PDT, 1000 EDT, 1500 BST, then again live, two hours later at 0900 PDT, 1200 EDT, 1700 BST.
Characterizing aggregation in proteins is paramount in understanding both biopharmaceutical product stability and efficacy. Product quality, both in terms of biological activity and immunogenicity can be highly influenced by the state of protein aggregation. A wide variety of aggregates are encountered in biopharmaceutical samples. These may be soluble or insoluble in nature, covalent or non-covalently bonded and produced by an aggregation process which may or may not be reversible. Observed sizes of stable aggregates range from small oligomers (nanometers) to insoluble micron-sized aggregates that may contain millions of monomer units.
The objectives in characterizing aggregation include:
* Quantitatively describing degree of aggregation (concentration by size class).
* Definition of acceptable quality, in development, in process or as a release test.
* Providing insight into the mechanisms of aggregation onset, as it begins at the nanoscale.
NanoSight has recently applied Nanoparticle Tracking Analysis (NTA) to protein aggregation. This technique allows nanoscale particles, such as protein aggregates, to be directly and individually visualized and counted in liquid in real-time to provide high-resolution particle size distribution profiles.
The technique is fast, robust, accurate and low cost, representing an attractive alternative or complement to existing methods of nanoparticle analysis such as Dynamic Light Scattering, DLS (also known as Photon Correlation Spectroscopy, PCS) or Electron Microscopy.
This webinar will also describe the NTA technique and compare its strengths and limitations with other techniques currently used. The format will be interactive, aiming to give participants an opportunity to pose questions on the challenges and techniques in this important topic. The webinar will be led by Dr Bob Carr, founder and CTO of NanoSight.
To register for the webinar, visit www.nanosight.com/webinar
To learn more about nanoparticle characterization using Nanoparticle Tracking Analysis, NTA, please visit the company website (www.nanosight.com) and register for the latest issue of NanoTrail, the company's electronic newsletter.
####
About NanoSight
NanoSight Limited, of Salisbury, UK, provides unique nanoparticle characterization technology. “Nanoparticle Tracking Analysis” (NTA) detects and visualizes populations of nanoparticles in liquids down to 10nm (material dependent) and measures the size of each particle from direct observations of diffusion. This particle-by-particle methodology goes beyond traditional light scattering techniques such as Dynamic Light Scattering (DLS), or Photon Correlation Spectroscopy (PCS), in providing high-resolution particle size distributions. Additionally NanoSight measures concentration and validates all data with video of particles moving under Brownian motion.
This characterization information is highly informative in understanding the more complex suspensions in biological systems, hence its wide application in development of drug delivery systems, viral vaccines, the study of toxicology of nanoparticles and their environmental fate and in biomarker detection. This real-time data also provides insight into the kinetics of protein aggregation and other time-dependent phenomena in a quantitative manner, at deeply sub-micron sizes.
NanoSight has more than 250 systems installed worldwide with users including BASF, BP, GlaxoSmithKline, Novartis, 3M Corp., Roche, Solvay and Unilever together with many universities and research institutes. There are currently 100+ third party papers citing NanoSight results, with this reference base growing very rapidly as NanoSight consolidates its key contribution to nanoparticle characterization. For more information, visit the NanoSight website (www.nanosight.com).
For more information, please click here
Contacts:
NetDyaLog Limited
39 de Bohun Court
Saffron Walden
Essex CB10 2BA
T +44 (0) 1799 521881
www.netdyalog.com
Copyright © NanoSight
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Tools
Turning up the signal November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||